Franck Priou

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 727 citations

Androgen-deprivation Therapy, Urology, Genitourinary Cancer +7

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology · 2015 · 454 citations

Urology, Genitourinary Cancer, Getug-afu15 Trial +7

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2

Stéphane Oudard, Stéphane Culine, Yann Vano et al. · European Journal of Cancer · 2014 · 141 citations

Urology, Metastatic Urothelial Carcinoma, Phase Ii Trial +6

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Gwénaëlle Gravis, Jean‐Marie Boher, Karim Fizazi et al. · European Urology · 2014 · 128 citations · Full text

Prognostic Factors, Urology, Genitourinary Cancer +6